Search

ECDC, after conducting rapid risk assessments, has concluded that the risk of importation of infectious diseases from North Africa to the EU is  considered to be low. From a public health perspective, the most urgent concern is related to the poor living conditions of the migrants, such as overcrowding and poor sanitation.

In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.

ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.

This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.

The Vaccine Preventable Diseases programme of ECDC has set up a working group to provide guidance to the European Union Member States on the potential introduction of varicella vaccination.

A large epidemic of measles has affected the EU/EEA Member States in the past three years, with 44 074 cases reported to ECDC by 30 Member States between 1 January 2016 and 31 March 2019.

This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.

This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination.

This document outlines the initial developments in EU/EEA member states and the UK regarding vaccine deployment plans and national vaccination strategies for COVID-19 vaccines, including interim considerations for priority groups, evidence to be considered for the prioritisation of target groups, logistical considerations and monitoring systems for post-marketing surveillance (e.g. vaccine coverage, safety, effectiveness and acceptance).